BVAC Ablative Chemotherapy Followed by Autologous Bone Marrow Transplantation for Patients With Advanced Lymphoma

Forty-one consecutive patients with lymphoma resistant to conventional combination chemotherapy have been entered into a study in which chemo-ablative therapy and autologous marrow rescue were used with curative intent. The actuarial proportion of 20 patients with Hodgkin's lymphoma remaining a...

Full description

Saved in:
Bibliographic Details
Published in:Blood 1990-06, Vol.75 (12), p.2276-2281
Main Authors: Gingrich, Roger D., Ginder, Gordon D., Burns, Linda J., Wen, B-Chen, Fyfe, Mary Anne
Format: Article
Language:English
Subjects:
Adolescent
Adult
Antineoplastic agents
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Biological and medical sciences
Bone Marrow Transplantation - adverse effects
Carmustine - administration & dosage
Combined Modality Therapy
Combined treatments (chemotherapy of immunotherapy associated with an other treatment)
Cyclophosphamide - administration & dosage
Cytarabine - administration & dosage
Etoposide - administration & dosage
Humans
Lymphoma - surgery
Lymphoma - therapy
Medical sciences
Middle Aged
Pharmacology. Drug treatments
Survival Analysis
Time Factors
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Forty-one consecutive patients with lymphoma resistant to conventional combination chemotherapy have been entered into a study in which chemo-ablative therapy and autologous marrow rescue were used with curative intent. The actuarial proportion of 20 patients with Hodgkin's lymphoma remaining alive and free of recurrent disease is 49%, while that for 21 patients with non-Hodgkin's lymphoma is 41%. Our clinical approach to these patients involved a strategy whereby lymphomatous nodes greater than 2 cm in diameter that persisted despite salvage chemotherapy were given boost radiation therapy immediately before chemo-ablation. However, patients with this variable had a significantly lower survival due to septic complications rather than recurrent disease. We conclude that the treatment strategy used in this study with some modification may improve further on the already high probability of long-term disease-free survival experienced by this group of patients.
ISSN:0006-4971
1528-0020
DOI:10.1182/blood.V75.12.2276.2276